Pharsight

Chiesi patents expiration

1. Bethkis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7939502 CHIESI Optimised formulation of tobramycin for aerosolization
Jun, 2022

(1 year, 10 months ago)

US6987094 CHIESI Optimized formulation of tobramycin for aerosolization
Sep, 2022

(1 year, 6 months ago)

US7696178 CHIESI Optimised formulation of tobramycin for aerosolization
Sep, 2022

(1 year, 6 months ago)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 12 October, 2012

Treatment: Management of cystic fibrosis patients

Dosage: SOLUTION;INHALATION

How can I launch a generic of BETHKIS before it's drug patent expiration?
More Information on Dosage

BETHKIS family patents

Family Patents

2. Cardene In 0.83% Sodium Chloride In Plastic Container patents expiration

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents

Family Patents

3. Cardene In 0.86% Sodium Chloride In Plastic Container patents expiration

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents

Family Patents

4. Cardene In 4.8% Dextrose In Plastic Container patents expiration

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER family patents

Family Patents

5. Cardene In 5.0% Dextrose In Plastic Container patents expiration

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(2 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER family patents

Family Patents

6. Cleviprex patents expiration

CLEVIPREX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856346 CHIESI Short-acting dihydropyridines
Jan, 2021

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5739152 CHIESI Pharmaceutical emulsion
Apr, 2015

(9 years ago)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(7 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(7 years from now)

US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2013

Drugs and Companies using CLEVIDIPINE ingredient

NCE-1 date: 01 August, 2012

Market Authorisation Date: 01 August, 2008

Treatment: Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage

CLEVIPREX family patents

Family Patents

7. Ferriprox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7049328 CHIESI Use for deferiprone
Jun, 2021

(2 years ago)

US8703156 CHIESI Liquid formulation for deferiprone with palatable taste
Oct, 2029

(5 years from now)

US11357731 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(14 years from now)

US11723874 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(14 years from now)

US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(14 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(14 years from now)

US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(14 years from now)

US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-859) Apr 30, 2024
Orphan Drug Exclusivity(ODE-417) Apr 30, 2028
Orphan Drug Exclusivity(ODE-419) Apr 30, 2028
Orphan Drug Exclusivity(ODE-418) Apr 30, 2028
Orphan Drug Exclusivity(ODE-16) Oct 14, 2018
New Chemical Entity Exclusivity(NCE) Oct 14, 2016
Orphan Drug Exclusivity(ODE) Oct 14, 2018

Drugs and Companies using DEFERIPRONE ingredient

NCE-1 date: 15 October, 2015

Market Authorisation Date: 20 April, 2018

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL; TABLET;ORAL

How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage

FERRIPROX family patents

Family Patents

8. Kengreal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6114313 CHIESI Pharmaceutical compositions for freeze drying
Dec, 2018

(5 years ago)

US6130208 CHIESI Formulation containing a nucleotide analogue
Jun, 2023

(9 months ago)

US9925265 CHIESI Methods of treating or preventing stent thrombosis
May, 2029

(5 years from now)

US8759316 CHIESI Maintenance of platelet inhibition during antiplatelet therapy
May, 2029

(5 years from now)

US9427448 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Nov, 2030

(6 years from now)

US8680052 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Mar, 2033

(8 years from now)

US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 22, 2020

Drugs and Companies using CANGRELOR ingredient

NCE-1 date: 23 June, 2019

Market Authorisation Date: 22 June, 2015

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

9. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566246 CHIESI Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US8535695 CHIESI Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US9265812 CHIESI Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US8329198 CHIESI Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US10238709 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US11338011 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US11510963 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US11052126 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US10695397 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US11141457 CHIESI Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents

10. Zyflo Cr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6183778 CHIESI Pharmaceutical tablet capable of liberating one or more drugs at different release rates
Sep, 2013

(10 years ago)

Drugs and Companies using ZILEUTON ingredient

Market Authorisation Date: 30 May, 2007

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

ZYFLO CR family patents

Family Patents